C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer

Publisher： Karger

E-ISSN： 2296-5262|39|5|266-271

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.5, 2016-04, pp. : 266-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 5, 2018-04 ,pp. : 336-342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of Bone Metastases in Patients with Castration-Resistant Prostate Cancer

By  

Urologia Internationalis, Vol. 92, Iss. 4, 2014-04 ,pp. : 377-386

Karger

Access to resources Recommend Favorite

Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone

By  

THE PROSTATE, Vol. 75, Iss. 12, 2015-07 ,pp. : 1329-1338

John Wiley & Sons Inc

Access to resources Recommend Favorite

The role of C‐reactive protein in prostate cancer

By  

CANCER, Vol. 119, Iss. 18, 2013-09 ,pp. : 3262-3264

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 772-776

Karger

Access to resources Recommend Favorite